This letter describes the first demonstration of clinical response to the anti-EGFR inhibitor gefitinib in a case of urothelial carcinoma of the renal pelvis harboring a rare EGFR double mutation. New mutations and unexpected clinical responses should be always explored through wide-spectrum mutational analyses.
Learning From Errors: Response to Gefitinib in Kidney Urothelial Carcinoma With EGFR Mutations / Fiorentino M; Giunchi F; Altimari A; Di Tullio P; Gruppioni E; Martorana G; Pinto C.. - In: THE ONCOLOGIST. - ISSN 1083-7159. - STAMPA. - 19:40(2014), pp. 430-430. [10.1634/theoncologist.2013-0346]
Learning From Errors: Response to Gefitinib in Kidney Urothelial Carcinoma With EGFR Mutations
FIORENTINO, MICHELANGELO;
2014
Abstract
This letter describes the first demonstration of clinical response to the anti-EGFR inhibitor gefitinib in a case of urothelial carcinoma of the renal pelvis harboring a rare EGFR double mutation. New mutations and unexpected clinical responses should be always explored through wide-spectrum mutational analyses.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
